

Curriculum Vitae Laurence ZITVOGEL

Contact:

INSERM, U1015
Institut Gustave Roussy
39, rue Camille Desmoulins
94805 Villejuif
France
Tel : 33-1- 42 11 50 41 Fax: 33-1- 42 11 60 94 E-mail : zitvogel@igr.fr

Informations personnelles

Date de naissance: 25 Dec. 1963
Sexe: féminin
Ville de naissance: Suresnes, France
Nationalité: France
Langues: français, anglais
1 enfant Ulysse Kroemer né le 25/10/2003
Adresse: 14-16 avenue de l'Observatoire 75006 Paris

Education

Date	Degré	Institution	Matière
1998	Habilitation (HDR)	Université Paris 11, Faculté de Médecine	Immunologie
1995	Thèse de sciences	Hôpital St. Louis, Université Paris 7	Immunologie
1992	DES	Ecole de Médecine, Université Paris 7	Oncologie médicale
1992	Thèse de Médecine	Ecole de Médecine, Université Paris 7	Oncologie
1987	Concours de l'Internat	Paris, Pitié Salpêtrière, Paris 6	Médecine
1982	Externat	Paris, Pitié Salpêtrière, Paris 6	Médecine
1981	Baccalauréat	Paris, Mention Bien	Mathématiques (C)

Postes/Affiliations

Dates	Title	Organization	City, Country
2005-	Directeur	Centre d'Investigations cliniques en Biothérapies Curie/IGR	Villejuif/Paris
2003-present	Professeur Agrégé	University Paris 11, Immunologie Biologie	Villejuif
2002-present	Directeur	Unité INSERM	Villejuif, France
2000-2004	Programm Coordinator	European Community	Brussels, Belgium
1995-2003	Clinicat (CCA), Biologie	IGR	Villejuif, France
1992-present	Oncologiste, Attaché	Institut Gustave Roussy, Department Pathologies mammaires	Villejuif, France
1992-1995	Junior Associate in Immunotherapy	Pittsburgh Cancer Institute	Pittsburgh, PA, USA
1987-1992	Internat de médecine	Ecole de Médecine, Paris	Paris, France

Honneurs/Distinctions

Date	Nom des Prix	Description
2012	Académie Nationale de Médecine	Membre correspondant, Oncologie Division 3
2012	European Academy of Cancer Science	Permanent Member, ECCO
2011	Prix Raymond Rosen FRM	Prix de Recherche Médicale
2008	Chevalier Ordre de la Légion d'Honneur	Ministère de la Recherche, France
2007	Prix Gallet & Breton Prize	Académie des Sciences, France
2007	INSERM Grand Prix	Recherche Translationnelle, France
2005	Prix Charles Oberling	Académie de Médecine, France
2000	Prix Gustave Roussy	Académie des Sciences, France
1999	Prix de la Chancellerie	Université Paris 5, France
1996	Prix de Recherche	LIGUE contre le Cancer, Comité Haute Loire, France
1995	Merit Award	Society for Biological Therapy, Nappa Valley, CA, USA
1994	Presidential Award	American Society for Clinical Oncology, LA, CA, USA
1992	Bourse d'étude	Fondation pour la Vocation Bleustein Blanchet

1992 Médaille d'Or de l'Internat Institut Gustave Roussy, Villejuif, France

Appartenances/Membres de sociétés savantes

<u>Date</u>	<u>Organisation</u>	<u>Position</u>
2013	Conseil d'Administration de Transgene	Membre élu
2012	Comité de revue DKFZ, Heidelberg, Allemagne	Expert Immunologie
2008	Current Opinion in Immunology (Springer)	Guest Editor
2008	Cell Death Differentiation (Nature Publishing Group)	Editeur invité
2007	Immunological Reviews (Munksgaard-Springer)	Editeur invité
2001-present	Foundation for Medical Research, France	Comité scientifique
2001-present	French Medical Research Council (INSERM)	Membre, Revue
1997-present	Expert of the French Ministry of Science	Membre, Revue
1999-2005	APCells/Anosys Biotech Company	Comité scientifique
1997	European Organization for Research and Treatment of Cancer (EORTC)	Comité scientifique
1996-2002	Club Francophone de Cellules Dendritiques	Comité directorial
1996-present	European Society for Medical Oncology	Membre
1996-present	American Association of Immunologists	Membre
1995-present	American Association for Cancer Research	Membre
1995-present	American Society for Clinical Oncology	Membre

Editeur de revues/journaux internationaux:

Editeur en chef: OncoImmunology

Fondateur: European Academy of Tumor Immunology

Editeur Associé Cancer Research depuis 2008, **Senior Editor** depuis 2009,

Editeur Associé J. Transl. Medicine depuis 2010.

Editeur Associé Frontiers in NK cell Biology, depuis 2011

Editeur Fondateur à Landes Publishing Group, Onco-Immunology (starting in 2012)

Editeur académique pour PLOs One depuis Septembre 2010

Prof. Laurence ZITVOGEL:

H factor L. Zitvogel: 75

Classée première femme immunologiste européenne en Juin 2013 par LabTimes, et 8ème immunologiste européenne

Meilleures Publications (parmi plus de 230), dans des Journaux à **facteur d'impact > 15 pour la plupart ou essais cliniques:**

[The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.](#)

Viaud S, Saccheri F, Mignot G, ... Boneca IG, Ghiringhelli F, [Zitvogel L](#).

Science. 2013 Nov 22;342(6161):971-6.

[Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.](#)

[Zitvogel L](#), Galluzzi L, Smyth MJ, Kroemer G.

Immunity. 2013 Jul 25;39(1):74-88.

[Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells.](#)

Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, Martins I, Schlemmer F, Michaud M, Kepp O, Sukkurwala AQ, ... [Zitvogel L](#), Kroemer G.

Immunity. 2013 Apr 18;38(4):729-41.

[Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists.](#)

Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, Prada N, Adjemian S, Catani JP, Freudenberg M, Galanos C, André F, Kroemer G, [Zitvogel L](#).

Cell Death Differ. 2014 Jan;21(1):69-78.

[Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8.](#)

Sukkurwala AQ, Martins I, Wang Y, Schlemmer F, Ruckenstein C, Durchschlag M, Michaud M, Senovilla L, Sistigu A, Ma Y, Vacchelli E, Sulpice E, Gidrol X, [Zitvogel L](#), Madeo F, Galluzzi L, Kepp O, Kroemer G.

Cell Death Differ. 2014 Jan;21(1):59-68.

[Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines.](#)

Hannani D, Locher C, Yamazaki T, Colin-Minard V, Vetizou M, Aymeric L, Viaud S, Sanchez D, Smyth MJ, Bruhns P, Kroemer G, [Zitvogel L](#).

Cell Death Differ. 2014 Jan;21(1):50-8.

[Neutralizing tumor-promoting chronic inflammation: a magic bullet?](#)

Coussens LM, [Zitvogel L](#), Palucka AK.

Science. 2013 Jan 18;339(6117):286-91.

[Immunogenic cell death in cancer therapy.](#)

Kroemer G, Galluzzi L, Kepp O, [Zitvogel L](#).

Annu Rev Immunol. 2013;31:51-72. Epub 2012 Nov 12.

[Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR\(+\) NK cell levels correlate with disease outcome.](#) Chaput N, Flament C, Locher C, Desbois M, Rey A, Rusakiewicz S, Poirier-Colame V, Pautier P, Le Cesne A, Soria JC, Paci A, Rosenzweig M, Klatzmann D, Eggermont A, Robert C, [Zitvogel L](#).

Oncoimmunology. 2013 Feb 1;2(2):e23080.

[Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.](#) Pautier P, Locher C, Robert C, Deroussent A, Flament C, Le Cesne A, Rey A, Bahleda R, Ribrag V, Soria JC, Vassal G, Eggermont A, [Zitvogel L](#), Chaput N, Paci A.

Oncoimmunology. 2013 Feb 1;2(2):e23079.

[An immunosurveillance mechanism controls cancer cell ploidy.](#)

Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, Galluzzi L, Adjemian S, ... [Zitvogel L](#), Castedo M, Kroemer G.

Science. 2012 Sep 28;337(6102):1678-84.

[Prognostic impact of vitamin B6 metabolism in lung cancer.](#)

Galluzzi L, Vitale I, Senovilla L, Olausson KA, Pinna G, Eisenberg T, Goubar A, Martins I, Michels J, Kratassiouk G, Carmona-Gutierrez D, Scoazec M, Vacchelli E, Schlemmer F, Kepp O, Shen S, Tailler M, Niso-Santano M, Morselli E, Criollo A, Adjemian S, Jemaà M, Chaba K, Pailleret C, Michaud M, Pietrocola F, Tajeddine N, de La Motte Rouge T, Araujo N, Morozova N, Robert T, Ripoche H, Commo F, Besse B, Validire P, Fouret P, Robin A, Dorvault N, Girard P, Gouy S, Pautier P, Jägemann N, Nickel AC, Marsili S, Paccard C, Servant N, Hupé P, Behrens C, Behnam-Motlagh P, Kohno K, Cremer I, Damotte D, Alifano M, Midttun O, Ueland PM, Lazar V, Dessen P, Zischka H, Chatelut E, Castedo M, Madeo F, Barillot E, Thomale J, Wistuba II, Sautès-Fridman C, [Zitvogel L](#), Soria JC, Harel-Bellan A, Kroemer G.

Cell Rep. 2012 Aug 30;2(2):257-69.

[Cardiac glycosides exert anticancer effects by inducing immunogenic cell death.](#)

Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, Yamazaki T, Sukkurwala AQ, Michaud M, Mignot G, Schlemmer F, Sulpice E, Locher C, Gidrol X, Ghiringhelli F, Modjtahedi N, Galluzzi L, André F, [Zitvogel L](#), Kepp O, Kroemer G. **Sci Transl Med.** 2012 Jul 18;4(143):143ra99.

[Inflammasomes in carcinogenesis and anticancer immune responses.](#)

[Zitvogel L](#), Kepp O, Galluzzi L, Kroemer G.

Nat Immunol. 2012 Mar 18;13(4):343-51. doi: 10.1038/ni.2224. Review.

[The secret ally: immunostimulation by anticancer drugs.](#)

Galluzzi L, Senovilla L, [Zitvogel L](#), Kroemer G.

Nat Rev Drug Discov. 2012 Feb 3;11(3):215-33. doi: 10.1038/nrd3626. Review

[Alternatively spliced NKp30 isoforms influence the prognosis of gastrointestinal stromal tumors.](#)

Nicolas F. Delahaye, Sylvie Rusakiewicz, Isabelle Martins, Cédric Ménard, Stéphan Roux, Luc Lyonnet, Pascale Paul, Caroline Flament, Nathalie Chaput, Michaela Semeraro, Véronique Minard-Colin, Vichnou Poirier-Colame, Véronique Baud, Hélène Authier, Saadia Kerdine-Römer, Marc Pallardy, Dominique Valteau-Couanet, Pascal Rihet, Jean-Yves Blay, Nicolas Isambert, Jean-François Emile, Eric Vivier, Axel Le Cesne, Guido Kroemer, and Laurence [Zitvogel](#).

Nat Med 2011, May 2.

[Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.](#)

Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, Boucontet L, Apetoh L, Ghiringhelli F, Casares N, Lasarte JJ, Matsuzaki G, Ikuta K, Ryffel B, Benlagha K, Tesnière A, Ibrahim N, Déchanet-Merville J, Chaput N, Smyth MJ, Kroemer G, [Zitvogel L](#).

J Exp Med. 2011 Mar 14;208(3):491-503.

[Immune parameters affecting the efficacy of chemotherapeutic regimens.](#)

[Zitvogel L](#), Kepp O, Kroemer G.

Nat Rev Clin Oncol. 2011 Mar;8(3):151-60.

[Targeting dendritic cell metabolism in cancer.](#)

[Zitvogel L](#), Kroemer G.

Nat Med. 2010 Aug;16(8):858-9.

[Chemotherapy and radiotherapy: cryptic anticancer vaccines.](#)

Ma Y, Kepp O, Ghiringhelli F, Apetoh L, Aymeric L, Locher C, Tesniere A, Martins I, Ly A, Haynes NM, Smyth MJ, Kroemer G, [Zitvogel L](#).

Semin Immunol. 2010 Jun;22(3):113-24. Epub 2010 Apr 18.

[Decoding cell death signals in inflammation and immunity.](#)

[Zitvogel L](#), Kepp O, Kroemer G.

Cell. 2010 Mar 19;140(6):798-804.

[Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells.](#)

Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, Boireau W, Rouleau A, Simon B, Lanneau D, De Thonel A, Multhoff G, Hamman A, Martin F, Chauffert B, Solary E, [Zitvogel L](#), Garrido C, Ryffel B, Borg C, Apetoh L, Rébé C, Ghiringhelli F.

J Clin Invest. 2010 Feb 1;120(2):457-71.

[The IKK complex contributes to the induction of autophagy.](#)

Criollo A, Senovilla L, Authier H, Maiuri MC, Morselli E, Vitale I, Kepp O, Tasdemir E, Galluzzi L, Shen S, Tailler M, Delahaye N, Tesniere A, De Stefano D, Younes AB, Harper F, Pierron G, Lavandro S, [Zitvogel L](#), Israel A, Baud V, Kroemer G.

EMBO J. 2010 Feb 3;29(3):619-31.

[Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors.](#) Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Schlemmer F, Tasdemir E, Uhl M, Génin P, Civas A, Ryffel B, Kanellopoulos J, Tschopp J, André F, Lidereau R, McLaughlin NM, Haynes NM, Smyth MJ, Kroemer G, [Zitvogel L](#).
Nat Med. 2009 Oct;15(10):1170-8.

[Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects.](#)
Zitvogel L, Kroemer G.
J Clin Invest. 2009 Aug;119(8):2127-30. doi: 10.1172/JCI39991. Epub 2009 Jul 20.

[Immunogenic and tolerogenic cell death.](#)
Green DR, Ferguson T, Zitvogel L, Kroemer G.
Nat Rev Immunol. 2009 May;9(5):353-63.

[CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer.](#)
Roux S, Apetoh L, Chalmin F, Ladoire S, Mignot G, Puig PE, Lauvau G, Zitvogel L, Martin F, Chauffert B, Yagita H, Solary E, Ghiringhelli F.
J Clin Invest. 2008 Nov;118(11):3751-61.

[The anticancer immune response: indispensable for therapeutic success?](#)
[Zitvogel L](#), Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G.
J Clin Invest. 2008 Jun;118(6):1991-2001. Review.

[Natural killer cell-directed therapies: moving from unexpected results to successful strategies.](#)
Terme M, Ullrich E, Delahaye NF, Chaput N, [Zitvogel L](#).
Nat Immunol. 2008 May;9(5):486-94. Review.

[Immunological aspects of cancer chemotherapy.](#)
[Zitvogel L](#), Apetoh L, Ghiringhelli F, Kroemer G.
Nat Rev Immunol. 2008 Jan;8(1):59-73. Review.

[Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.](#)
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delalogue S, Tursz T, Kroemer G, [Zitvogel L](#).
Nat Med. 2007 Sep;13(9):1050-9.

[Calreticulin exposure dictates the immunogenicity of cancer cell death.](#)

Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Métivier D, Larochette N, van Endert P, Ciccocanti F, Piacentini M, Zitvogel L, Kroemer G.

Nat Med. 2007 Jan;13(1):54-61.

[Cancer despite immunosurveillance: immunoselection and immunosubversion.](#)

Zitvogel L, Tesniere A, Kroemer G.

Nat Rev Immunol. 2006 Oct;6(10):715-27. Epub 2006 Sep 15. Review.

[A novel dendritic cell subset involved in tumor immunosurveillance.](#) Taieb J, Chaput N, Ménard C, Apetoh L, Ullrich E, Bonmort M, Péquignot M, Casares N, Terme M, Flament C, Opolon P, Lecluse Y, Métivier D, Tomasello E, Vivier E, Ghiringhelli F, Martin F, Klatzmann D, Poynard T, Tursz T, Raposo G, Yagita H, Ryffel B, Kroemer G, Zitvogel L.

Nat Med. 2006 Feb;12(2):214-9.

[In vivo veritas.](#)

Zitvogel L, Tursz T.

Nat Biotechnol. 2005 Nov;23(11):1372-4.

[Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.](#) Borg C, Terme M, Taïeb J, Ménard C, Flament C, Robert C, Maruyama K, Wakasugi H, Angevin E, Thielemans K, Le Cesne A, Chung-Scott V, Lazar V, Tchou I, Crépineau F, Lemoine F, Bernard J, Fletcher JA, Turhan A, Blay JY, Spatz A, Emile JF, Heinrich MC, Mécheri S, Tursz T, Zitvogel L.

J Clin Invest. 2004 Aug;114(3):379-88.

[Exosomes: composition, biogenesis and function.](#)

Théry C, Zitvogel L, Amigorena S.

Nat Rev Immunol. 2002 Aug;2(8):569-79.

[Malignant effusions and immunogenic tumour-derived exosomes.](#) Andre F, Scharz NE, Movassagh M, Flament C, Pautier P, Morice P, Pomel C, Lhomme C, Escudier B, Le Chevalier T, Tursz T, Amigorena S, Raposo G, Angevin E, Zitvogel L.

Lancet. 2002 Jul 27;360(9329):295-305.

[Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming.](#)
Wolfers J, Lozier A, Raposo G, Regnault A, Théry C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, Angevin E, Amigorena S, [Zitvogel L](#).

Nat Med. 2001 Mar;7(3):297-303.

[Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo.](#) Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, [Zitvogel L](#).

Nat Med. 1999 Apr;5(4):405-11.

[Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes.](#)

[Zitvogel L](#), Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S.

Nat Med. 1998 May;4(5):594-600.

[Dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity.](#)

Mayordomo JI, Zorina T, Storkus WJ, [Zitvogel L](#), Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, et al.

Nat Med. 1995 Dec;1(12):1297-302.